BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 06, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ruconest conestat alfa: Phase II data

Top-line data from the open-label, Dutch Phase II OPERA trial in 25 asymptomatic HAE patients with a history of frequent attacks showed that once-weekly 50 U/kg Ruconest for 8 weeks reduced the average number of HAE attacks per week compared...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >